Noxopharm Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Noxopharm.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 15.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation
Aug 24
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Jan 04We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 22Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Feb 27We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth
Nov 10Is Noxopharm (ASX:NOX) Using Debt Sensibly?
Jun 04Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 17These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively
Sep 04In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Noxopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 2 | -4 | -1 | -1 | N/A |
| 3/31/2024 | 3 | -8 | -3 | -3 | N/A |
| 12/31/2023 | 4 | -12 | -6 | -6 | N/A |
| 9/30/2023 | 5 | -14 | -9 | -9 | N/A |
| 6/30/2023 | 6 | -15 | -11 | -11 | N/A |
| 3/31/2023 | 6 | -15 | -8 | -8 | N/A |
| 12/31/2022 | 7 | -15 | -5 | -5 | N/A |
| 9/30/2022 | 6 | -17 | -10 | -10 | N/A |
| 6/30/2022 | 5 | -19 | -14 | -14 | N/A |
| 3/31/2022 | 6 | -15 | -14 | -14 | N/A |
| 12/31/2021 | 6 | -11 | -14 | -14 | N/A |
| 9/30/2021 | 6 | -10 | -11 | -11 | N/A |
| 6/30/2021 | 6 | -9 | -9 | -9 | N/A |
| 3/31/2021 | 6 | -5 | -10 | -10 | N/A |
| 12/31/2020 | 6 | 0 | -12 | -12 | N/A |
| 9/30/2020 | 7 | 0 | -11 | -11 | N/A |
| 6/30/2020 | 8 | 0 | -11 | -11 | N/A |
| 3/31/2020 | 6 | -7 | -12 | -12 | N/A |
| 12/31/2019 | 4 | -15 | -12 | -12 | N/A |
| 9/30/2019 | 4 | -13 | -11 | -11 | N/A |
| 6/30/2019 | 4 | -11 | -10 | -10 | N/A |
| 3/31/2019 | 4 | -11 | -9 | -9 | N/A |
| 12/31/2018 | 3 | -10 | -8 | -8 | N/A |
| 9/30/2018 | 2 | -14 | -9 | -9 | N/A |
| 6/30/2018 | 1 | -18 | -9 | -9 | N/A |
| 3/31/2018 | 1 | -16 | N/A | -7 | N/A |
| 12/31/2017 | 1 | -14 | N/A | -5 | N/A |
| 9/30/2017 | 1 | -8 | N/A | -4 | N/A |
| 6/30/2017 | 0 | -3 | N/A | -3 | N/A |
| 3/31/2017 | 0 | -3 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NOX's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if NOX's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if NOX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if NOX's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: Insufficient data to determine if NOX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NOX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Noxopharm Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|